Emerging mechanisms of immunotherapy resistance in sarcomas

Abstract

Sarcomas are a heterogeneous group of over 150 mesenchymal neoplasms of bone and soft tissue. Clinical prognosis remains poor in the metastatic and refractory setting, despite treatment with traditional chemotherapies. A subset of sarcoma patients can exhibit remarkable responses to novel immune therapies; however, most patients will not respond. Emerging data from genetic and transcriptomic datasets suggests that patients who are resistant to checkpoint inhibitor monotherapy may have low expression of immune-related genes, suggesting that the sarcoma was not sufficiently immunogenic to trigger or maintain an immune response to generate tumor-specific immune effector cells. In this review, we discuss the emerging data surrounding potential mechanisms of resistance, including various biomarkers explored in clinical trials of immune therapy for sarcomas. We also review future directions in clinical trials that are focused on boosting tumor immunogenicity to improve the activity of checkpoint inhibitors, as well as adoptive cellular therapy approaches to bypass deficiencies in neoantigens or antigen presentation.

Keywords

Sarcoma / immune therapy / immune resistance / immunogenicity / chemotherapy / clinical trials

References

[1] Kallen ME.The 2020 WHO Classification: what’s new in soft tissue tumor pathology?.Am J Surg Pathol2021;45:e1-e23

[2] Verschoor AJ,Marréaud S.Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study.Clin Sarcoma Res2020;10:18 PMCID:PMC7488114

[3] Coley WB.The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.Clin Orthop Relat Res1991;(262):3-11.

[4] Wilky BA,Subhawong TK.Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.Lancet Oncol2019;20:837-48

[5] Florou V,Wieder E.Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.J Immunother Cancer2019;7:213 PMCID:PMC6686562

[6] Wagner MJ,Patel SP.Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).J Immunother Cancer2021;9:e002990 PMCID:PMC8330584

[7] D’Angelo SP,Van Tine BA.A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401).J Clin Oncol2017;35:11007

[8] D’Angelo SP,Merchant MS.Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 ^c259T cells in synovial sarcoma.Cancer Discov2018;8:944-57 PMCID:PMC8092079

[9] Tawbi HA,Bolejack V.Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol2017;18:1493-501 PMCID:PMC7939029

[10] Naqash AR,Moore N.Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).J Clin Oncol2021;39:11519

[11] Chen DS.Oncology meets immunology: the cancer-immunity cycle.Immunity2013;39:1-10

[12] Galluzzi L,Warren S.Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.J Immunother Cancer2020;8:e000337 PMCID:PMC7064135

[13] Dufresne A,Ménétrier-Caux C.Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma.Oncoimmunology2020;9:1792036 PMCID:PMC7458655

[14] Chávez-Galán L,Vesin D.Much More than M1 and M2 macrophages, there are also CD169(+) and TCR(+) macrophages.Front Immunol2015;6:263 PMCID:PMC4443739

[15] Wherry EJ.Molecular and cellular insights into T cell exhaustion.Nat Rev Immunol2015;15:486-99 PMCID:PMC4889009

[16] Spranger S,Corrales L.Tumor and host factors controlling antitumor immunity and efficacy of cancer immunotherapy.Adv Immunol2016;130:75-93 PMCID:PMC4864964

[17] Wisdom AJ,Hong CS.Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.Nat Commun2020;11:6410 PMCID:PMC7746723

[18] Hildebrand KM,McNeil R.The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.PLoS One2021;16:e0253864 PMCID:PMC8270133

[19] Gutierrez WR,McGivney GR.Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models.Sci Rep2021;11:1098 PMCID:PMC7806664

[20] Petitprez F,Keung EZ.B cells are associated with survival and immunotherapy response in sarcoma.Nature2020;577:556-60

[21] Hu C,Huang Z.Comprehensive profiling of immune-related genes in soft tissue sarcoma patients.J Transl Med2020;18:337 PMCID:PMC7465445

[22] Riaz N,Havel JJ,Desrichard A.The role of neoantigens in response to immune checkpoint blockade.Int Immunol2016;28:411-9 PMCID:PMC4986233

[23] Goodman AM,Bazhenova L.Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers.Mol Cancer Ther2017;16:2598-608 PMCID:PMC5670009

[24] Chalmers ZR,Fabrizio D.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med2017;9:34 PMCID:PMC5395719

[25] Groisberg R,Conley AP.Genomics, morphoproteomics, and treatment patterns of patients with alveolar soft part sarcoma and response to multiple experimental therapies.Mol Cancer Ther2020;19:1165-72 PMCID:PMC8386165

[26] Painter CA,Tomson BN.The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.Nat Med2020;26:181-7

[27] Mc Granahan N,Rosenthal R.Clonal neoantigens elict T cell immunoreactivity and sensitivity to immune checkpoint blockade.Science2016;351:1463-9 PMCID:PMC4984254

[28] Rizvi NA,Snyder A.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2016;348:124-8. PMCID:PMC4993154

[29] Chae YK,Lopes G.Clinical and immunological implications of frameshift mutations in lung cancer.J Thorac Oncol2019;14:1807-17

[30] George S,Demetri GD.Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma.Immunity2017;46:197-204 PMCID:PMC5408320

[31] Kato S,Walavalkar V,Sharabi A.Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res2017;23:4242-50 PMCID:PMC5647162

[32] Pollack SM,Baker KK.Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial.JAMA Oncol2020;6:1778-82 PMCID:PMC7489365

[33] DuBois S.Markers of angiogenesis and clinical features in patients with sarcoma.Cancer2007;109:813-9

[34] Shurell E,Crompton JG.Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.Oncotarget2016;7:64300-8 PMCID:PMC5325443

[35] Hack SP,Wang Y.Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities.Front Immunol2020;11:598877 PMCID:PMC7674951

[36] Martin-Broto J,Grignani G.Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.J Immunother Cancer2020;8:e001561 PMCID:PMC7674086

[37] Xie L,Sun X.Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.J Immunother Cancer2020;8:e000798 PMCID:PMC7223462

[38] Zhang M,Chen Y,Wang Q.TGF-β signaling and resistance to cancer therapy.Front Cell Dev Biol2021;9:786728 PMCID:PMC8669610

[39] Verrecchia F.Transforming growth factor-β signaling plays a pivotal role in the interplay between osteosarcoma cells and their microenvironment.Front Oncol2018;8:133 PMCID:PMC5937053

[40] Kim BG,Choi SH,Driscoll JJ.Novel therapies emerging in oncology to target the TGF-β pathway.J Hematol Oncol2021;14:55 PMCID:PMC8022551

[41] Ghisoli M,Mennel R.Three-year follow up of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing’s sarcoma.Mol Ther2016;24:1478-83 PMCID:PMC5023386

[42] Läubli H,Schwarz F.Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.Proc Natl Acad Sci U S A2014;111:14211-6 PMCID:PMC4191788

[43] Lübbers J,van Kooyk Y.Modulation of immune tolerance via siglec-sialic acid interactions.Front Immunol2018;9:2807 PMCID:PMC6293876

[44] de Wall S, Santegoets KCM, van Houtum EJH, Büll C, Adema GJ. Sialoglycans and siglecs can shape the tumor immune microenvironment.Trends Immunol2020;41:274-85

[45] Sun J,Sanmamed MF.Siglec-15 as an emerging target for next-generation cancer immunotherapy.Clin Cancer Res2021;27:680-8

[46] Fan MK,Chen W.Siglec-15 promotes tumor progression in osteosarcoma via DUSP1/MAPK pathway.Front Oncol2021;11:710689 PMCID:PMC8322944

[47] Li B,Wang X.Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis.Oncoimmunology2020;9:1807291 PMCID:PMC7480813

[48] Dobrenkov K,Gu J,Cheung NK.Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.Pediatr Blood Cancer2016;63:1780-5 PMCID:PMC5215083

[49] Carvajal RD,Ryan CW.Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: a randomized phase 2 trial.J Clin Oncol2014;32:10520

[50] Miwa S,Tanzawa Y.Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma.Cancer2017;123:1576-84

[51] Nowicki TS,Cheung-Lau G.A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab.Clin Cancer Res2019;25:2096-108 PMCID:PMC6445780

[52] D’angelo SP,Van Tine BA.Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Lancet Oncol2018;19:416-26

[53] Teng MW,Ribas A.Classifying cancers based on T-cell infiltration and PD-L1.Cancer Res2015;75:2139-45 PMCID:PMC4452411

[54] Dancsok AR,Gao D.Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas.Mod Pathol2019;32:1772-85

[55] van Erp AEM,Hillebrandt-Roeffen MHS.Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8⁺ lymphocytes in primary sarcomas is subtype dependent.Oncotarget2017;8:71371-84 PMCID:PMC5642642

[56] Nafia I,Bortolotto D.IDO targeting in sarcoma: biological and clinical implications.Front Immunol2020;11:274 PMCID:PMC7066301

[57] Pollack SM,Yearley JH.T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.Cancer2017;123:3291-304 PMCID:PMC5568958

[58] D’Angelo SP,Agaram NP.Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.Hum Pathol2015;46:357-65 PMCID:PMC5505649

[59] Sorbye SW,Valkov A.Prognostic impact of lymphocytes in soft tissue sarcomas.PLoS One2011;6:e14611 PMCID:PMC3029277

[60] Tumeh PC,Yearley JH.PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature2014;515:568-71 PMCID:PMC4246418

[61] Keung EZ,Salazar R.Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab.Clin Cancer Res2020;26:1258-66 PMCID:PMC7731262

[62] Helmink BA,Gao J.B cells and tertiary lymphoid structures promote immunotherapy response.Nature2020;577:549-55 PMCID:PMC8762581

[63] Chen L,Siegel N.The immunosuppressive niche of soft-tissue sarcomas is sustained by tumor-associated macrophages and characterized by intratumoral tertiary lymphoid structures.Clin Cancer Res2020;26:4018-30 PMCID:PMC8772618

[64] Italiano A,Bompas E.PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: a multicenter phase II trial.J Clin Oncol2021;39:11507

[65] Toulmonde M,Adam J.Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial.JAMA Oncol2018;4:93-7 PMCID:PMC5833654

[66] Meyer C,Costa-Nunes CM.Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.Cancer Immunol Immunother2014;63:247-57

[67] Diaz-Montero CM,Nishimura MI,Cole DJ.Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.Cancer Immunol Immunother2009;58:49-59 PMCID:PMC3401888

[68] Highfill SL,Giles AJ.Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.Sci Transl Med2014;6:237ra67 PMCID:PMC6980372

[69] Zhao L.Engineered T cell therapy for cancer in the clinic.Front Immunol2019;10:2250 PMCID:PMC6798078

[70] Kakimoto T,Kageyama S.Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.Oncol Lett2019;17:3937-43 PMCID:PMC6403520

[71] Iura K,Ishii T.MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.Virchows Arch2017;471:383-92

[72] Ramachandran I,Dryer-Minnerly R.Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.J Immunother Cancer2019;7:276 PMCID:PMC6813983

[73] Tabak SA,Fathy Y.HER-2 immunohistochemical expression in bone sarcomas: a new hope for osteosarcoma patients.Open Access Maced J Med Sci2018;6:1555-60 PMCID:PMC6182517

[74] Xiao W,Wen X.Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor α-positive rhabdomyosarcoma.Cancer2020;126 Suppl 9:2093-100

[75] D’Angelo SP,Kelly CM.Pilot study of NKTR214 and nivolumab in patients with sarcomas.J Clin Oncol2019;37(15_suppl):11010.

[76] Zhang S,Black RG.Systemic interferon-γ increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial.Cancer Immunol Res2019;7:1237-43 PMCID:PMC6677581

[77] Fabian KP,Hodge JW.From immunogenic cell death to immunogenic modulation: select chemotherapy regimens induce a spectrum of immune-enhancing activities in the tumor microenvironment.Front Oncol2021;11:728018 PMCID:PMC8419351

[78] Wang YJ,Yu J.Immunogenic effects of chemotherapy-induced tumor cell death.Genes Dis2018;5:194-203 PMCID:PMC6176216

[79] Pfirschke C,Rickelt S.Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy.Immunity2016;44:343-54 PMCID:PMC4758865

[80] Zitvogel L,Smyth MJ.Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.Immunity2013;39:74-88

[81] Mattarollo SR,Duret H,Zitvogel L.Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.Cancer Res2011;71:4809-20

[82] Ramakrishnan R,Nagaraj S.Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.J Clin Invest2010;120:1111-24 PMCID:PMC2846048

[83] Sistigu A,Vacchelli E.Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.Nat Med2014;20:1301-9

[84] Gabrilovich DI.Myeloid-derived suppressor cells as regulators of the immune system.Nat Rev Immunol2009;9:162-74 PMCID:PMC2828349

[85] Germano G,Simone M.Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.Cancer Res2010;70:2235-44

[86] Ito K,Abe T.Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.Cancer Sci2017;108:2273-80 PMCID:PMC5665763

[87] Livingston MB,Robinson MM.Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma.Clin Cancer Res2021;27:6424-31

[88] Gordon EM,Kim K.SAINT: results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.J Clin Oncol2019;37:11016.

[89] Nathenson M,Carr ND.Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): report of LMS cohort.J Clin Oncol2020;38:11559

[90] Le Cesne A,Blay JY.Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.Eur J Cancer2019;119:151-7

[91] Kelly CM,Bowler T.Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial.JAMA Oncol2020;6:402-8 PMCID:PMC6990941